ESPR Q2 2024 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$74M+186.3% YoY

Gross Profit

$58M78.9% margin

Operating Income

$3M3.5% margin

Net Income

-$62M-83.9% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

-46.4%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$352M

Total Liabilities

$697M

Stockholders' Equity

-$344M

Cash & Equivalents

$189M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$74M	$26M	+186.3%
Gross Profit	$58M	$19M	+206.4%
Operating Income	$3M	-$37M	+107.0%
Net Income	-$62M	-$50M	-24.0%

Revenue Segments

Collaboration Revenue

$46M62%

Product

$28M38%